3 days ago · Fenaux succeeds Simon Bedson, who is retiring after seven years as Vertex’s senior vice president and general manager, international commercial operations and nearly 30 years in pharma.

Aug 23, 2018 · Vertex’s commercial lead Simon Bedson (pictured above) is set to retire from his post as senior vice president and general manager, international commercial operations, after seven years’ service with the company.

Mr. Simon Bedson serves as Senior Vice President and General Manager of International Commercial Operations at Vertex Pharmaceuticals Incorporated. Bedson joined Vertex in 2011 and leads Vertex's global expansion.

Jul 17, 2018 · In a letter to the U.K. patient community, Vertex senior vice president and international general manager Simon Bedson wrote that the offer "does not take into account the vast time and resources...

Mar 10, 2025 · Simon Bedson, International General Manager at Vertex: “We’re very pleased that lumacaftor/ivacaftor received a positive PBAC recommendation for CF patients in Australia, which brings those who...

GM Europe at Vertex Pharmaceuticals · Berufserfahrung: Retired · Standort: Genf · 500+ Kontakte auf LinkedIn. Sehen Sie sich das Profil von Simon Bedson auf LinkedIn, einer professionellen...

Mar 5, 2014 · Simon Bedson, Senior Vice President and International General Manager at Vertex, has three decades of pharmaceutical and biotech industry experience. He joined Vertex in 2011 to lead the...

View the executive profile of Simon Bedson, Senior Vice President and General Manager, International Commercial Operations at Vertex Pharmaceuticals Incorporated, on Equilar ExecAtlas to see current and past work history and gain access to Simon Bedson's network of 27 business contacts.

Mr. Bedson joined Vertex in 2011 to lead Vertex’s global expansion and is the company’s Senior Vice President and General Manager, International Commercial Operations.

We are disappointed but not surprised by today’s decision by NICE not to recommend the transformational lumacaftor/ivacaftor combination cystic fibrosis treatment Orkambi for use in England by the NHS. It is clear that the accepted clinical outcomes produced by …